In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and ...

Jan. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in ...

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...